TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04521218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Joint Manipulation
Description: Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Sustained Natural apophyseal glides
Description: Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold
Study: NCT01498172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3 ASCI
Description: 5 doses every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3 ASCI
Description: 5 doses every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3 ASCI
Description: 5 doses every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 intravesical dose /week for 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 intravesical dose /week for 6 weeks
Study: NCT00471133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xenogeneic Tyrosinase DNA Vaccine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System for Intramuscular Electroporation
Study: NCT03244553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 5 day treatment
Study: NCT03186976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive Risk Factor Control
Description: 1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Recommendations based on current guidelines
Study: NCT01910688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA treatment
Description: If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
Study: NCT03596294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single i.v. dose of 600 mg rifampicin for 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single i.v. dose of 600 mg rifampicin for 30 min
Study: NCT02478671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TR Band
Description: The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
Study: NCT02534961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
Study: NCT03345004

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diamyd
Description: Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Oil suspension of Vitamin D

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Diamyd
Description: Alhydrogel® only

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Vitamin D
Description: Placebo oil suspension for Vitamin D
Study: NCT04649723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: single oral dose, 600 mg, fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: single oral dose, 200 mg, fasted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR1459
Description: single oral dose, 200 mg, fasted.
Study: NCT01531179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri 100 million CFU/day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 months
Study: NCT01599962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: single administration, 90mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinacalcet
Description: single administration, 90mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration
Study: NCT02837653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counselling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise for LBP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise for LBP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Thermotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial Thermotherapy
Study: NCT02260986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
Study: NCT03175458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift,implant placement,tenting
Description: elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus lift,implant placement,bovine bone
Description: sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
Study: NCT02194491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]AS2471907
Description: intravenous radiotracer
Study: NCT01406717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIL1033
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Study: NCT02194491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging scanning procedure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging scanning procedure
Study: NCT03596294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline (0.9% sodium chloride)
Description: Single i.v infusion of 500 mL saline for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline (0.9% sodium chloride)
Description: Single i.v infusion of 500 mL saline for 30 min
Study: NCT02194491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3662
Description: oral
Study: NCT02825810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical motor control
Description: Intervention will consist in a tailored exercise training following a previous published motor control protocol
Study: NCT03969537

Intervention type: OTHER
Intervention: Telemedicine follow-up visit
Description: Study participants will experience two telemedicine (live audio/video) visits.
Study: NCT03838315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization with Soft Tissue Mobilization
Description: Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique
Study: NCT01784263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy
Description: Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Treatment
Description: In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
Study: NCT00520468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 40,000 units injected under the skin (SQ) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: 300 mg (tablets) by mouth daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300 mcg injected under the skin (SQ) two times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg per day for 7 days, taper over 1 month
Study: NCT01271972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Study: NCT02375685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Study: NCT01271972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Study: NCT00087412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT03838315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization without Soft Tissue Mobilization
Description: Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.
Study: NCT00087412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00009893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT03526146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Preventing Loss of Independence through Exercise (PLIE)
Description: PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
Study: NCT03888690

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Headset
Description: Standardized procedures, with or without Virtual Reality Headset.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Headset
Description: Standardized procedures, with or without Virtual Reality Headset.
Study: NCT02826499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediguard
Description: It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
Study: NCT01793935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensoril®
Description: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
Study: NCT02087592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training plus mediterranean diet
Study: NCT01363440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Study: NCT03552705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
Study: NCT01197248

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystocele plication
Description: placement of sutures over the pubocervical fascia during the cystocele repair
Study: NCT01363440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser Photocoagulation
Description: Laser therapy
Study: NCT02981251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education with support by trained female health volunteer
Description: Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
Study: NCT03695094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Concomitant administration of levetiracetam (LEV) at therapeutic dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Concomitant administration of levetiracetam (LEV) at therapeutic dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Concomitant administration of lamotrigine (LTG) at therapeutic dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Concomitant administration of lamotrigine (LTG) at therapeutic dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Concomitant administration of brivaracetam (BRV) at therapeutic dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Concomitant administration of brivaracetam (BRV) at therapeutic dosage
Study: NCT02323334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally
Study: NCT01197248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Plication
Description: Avoid sutures over pubocervical fascia during cystocele plication
Study: NCT02323334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally